|
|
Embecta Corp (NASDAQ: EMBC) |
|
Price: $5.1400
$0.09 
1.782%
|
| Day's High:
| $5.235000133514404
| Week Perf:
| 2.19 %
|
| Day's Low: |
$ 4.92 |
30 Day Perf: |
41.21 % |
| Volume (M): |
2,765,916 |
52 Wk High: |
$ 15.55 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$9.16 |
| Open: |
$5.00 |
52 Wk Low: |
$2.77 |
|
|
| Market Capitalization (Millions $) |
301 |
| Shares
Outstanding (Millions) |
59 |
| Employees |
1,850 |
| Revenues (TTM) (Millions $) |
1,020 |
| Net Income (TTM) (Millions $) |
88 |
| Cash Flow (TTM) (Millions $) |
-40 |
| Capital Exp. (TTM) (Millions $) |
8 |
Business Description
The company is a global medical device company that focuses on providing solutions to improve the health and well-being of people living with diabetes. Their products are used by nearly 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes. The company has a broad portfolio of marketed products, including a variety of pen needles, syringes, and safety injection devices. The company also seeks to promote advances in diabetes care through thought leadership and engagement with the diabetes community. They have three manufacturing sites located in Ireland, the United States, and China, and they distribute their products through a variety of channels, including retail, hospitals, pharmacies, and other institutional channels. The company uses a combination of patents, copyrights, trademarks, trade secrets, nondisclosure agreements, and other measures to establish and protect their proprietary rights.
In summary, the company is a leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. With close to 100 years of experience in the industry, the company has become one of the most widely recognized and respected brands in diabetes management in the world.
The company's broad portfolio of products, including pen needles, syringes, and safety injection devices, as well as its proprietary digital application designed to assist people with managing their diabetes, has made a significant impact in diabetes care. The company's commitment to research and development, coupled with its global operations and strong financial performance, positions it for continued growth and success in the future.
Company Address: 300 Kimball Drive, Suite 300 Parsippany 7054 NJ
Company Phone Number: 401-0000 Stock Exchange / Ticker: NASDAQ EMBC
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Dividend
Published Thu, Feb 6 2025 11:00 AM UTC
A Financial Balancing Act: Embecta Declares Dividend Amid Financial Challenges and Diabetes AdvocacyIn a strategic move that illustrates both resilience and commitment, Embecta Corp. has declared a quarterly cash dividend of $0.15 per share for all issued and outstanding shares of its common stock. This announcement, made on February 6, 2025, underscores the company s dedica...
|
| Dividend
Published Tue, Nov 26 2024 11:00 AM UTC
Innovative Approaches Amid Financial Hurdles: Embecta Corp. Declares Quarterly Dividend and Rings Nasdaq Bell for Diabetes AwarenessIn a notable announcement from Embecta Corp. the New Jersey-based medical technology company has declared a quarterly cash dividend of $0.15 per share for its common stock, according to a press release dated November 26, 2024. This declaration u...
|
| Management Announcement
Published Thu, Nov 7 2024 11:30 AM UTC
November is National Diabetes Awareness Month, a time dedicated to raising awareness about diabetes and promoting better care solutions for those affected by this chronic disease. In a bold display of commitment to advancing diabetes management, Embecta Corp recently celebrated this important month by ringing the Nasdaq Closing Bell, joined by key diabetes advocacy groups. T...
|
| Product Service News
Published Tue, Sep 3 2024 10:30 AM UTC
Empowering Type 2 Diabetes Management: FDA Clears embecta s Revolutionary Disposable Insulin Patch PumpIn a landmark achievement poised to transform the landscape of diabetes care, embecta has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative disposable insulin delivery system. This state-of-the-art patch pump, meticulously designe...
|
| Dividend
Published Fri, Aug 9 2024 10:00 AM UTC
Embecta Corp. Boosts Shareholder Confidence with Quarterly Dividend Amid Strong Financial Performance
Embecta Corp., a prominent player in the healthcare sector, recently announced a quarterly cash dividend of $0.15 per share, reflecting its ongoing commitment to delivering value to shareholders. The dividend, which will be payable on September 13, 2024, is aimed at stoc...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
1.48 $ |
| Revenues (TTM) |
17.43 $
|
| Cash Flow (TTM) |
- |
| Cash |
3.67 $
|
| Book Value |
-
|
| Dividend (TTM) |
0.46 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
551,189 |
| Net
Income per Employee (TTM) |
47,297 |
| Receivable Turnover Ratio (TTM) |
6.57 |
| Inventory Turnover Ratio (TTM) |
2.19 |
| Asset Turnover Ratio (TTM) |
0.91 |
|
|
| Per Share |
|
| Earnings (TTM) |
1.48 $
|
| Revenues (TTM) |
17.43 $ |
| Cash Flow (TTM) |
- |
| Cash |
3.67 $
|
| Book Value |
- |
| Dividend (TTM) |
0.46 $ |
|
|
| |
| United States |
|
 127.75 % |
of total Revenue |
| Non-US |
|
150.02 % |
of total Revenue |
| Pen Needles |
|
190.5 % |
of total Revenue |
| Syringes |
|
34.49 % |
of total Revenue |
| Safety |
|
39.86 % |
of total Revenue |
| Product and Service, Other |
|
8.54 % |
of total Revenue |
| Manufacturing Facility |
|
4.38 % |
of total Revenue |
| |
On November 26 2024 the Embecta provided following guidance
nnEmbecta Corp. Releases Financial Results for Fiscal Year 2024 and Announces Strategic Changes for Future Growthnn
nnPARSIPPANY, N.J., November 26, 2024nn – Embecta Corp. (Nasdaq: EMBC), a leading global entity in diabetes care, has announced its financial outcomes for both the fourth quarter and the complete fiscal year 2024, concluding on September 30, 2024. In addition to this announcement, the company has provided preliminary financial projections for fiscal year 2025, indicating a forward-looking approach as it navigates the challenges and opportunities ahead. As part of its strategic realignment, Embecta has also revealed the discontinuation of its insulin patch pump program and has initiat...
|
|
|
0.53%